Literature DB >> 9851648

Severe progression of ALS/MND after intervertebral discectomy.

M Sostarko1, D Vranjes, V Brinar, Z Brzovic.   

Abstract

We observed seven patients who developed their first signs and symptoms of motor neuron disease together with signs of protrusion/prolapse of intervertebral disc. The age of the patients was between 55 and 67, of which one female and six male patients. All of them suffered from cervical spine pain or low back pain. The female patient and one male patient developed weakness in the small feet muscles as initial symptom and they complained of paresthesia along dermatomes L5S1 and of severe pain. The other five patients developed wasting of the hands muscles. They had a rather mild pain in the cervical spine and early morning paresthesia as well as severe causalgia along dermatomes C5C6 or C6C7. After the diagnosis of compressive radiculopathy in all patients, they underwent surgical treatment and very soon developed very severe progression of muscle wasting which included muscles of limbs, trunk and bulbar innervated muscles with signs and symptoms of lower and upper motor neuron lesion. Five patients died from 12 to 15 months after surgical treatment and two patients are still living.

Entities:  

Mesh:

Year:  1998        PMID: 9851648     DOI: 10.1016/s0022-510x(98)00197-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Repetitive nerve stimulation as a diagnostic aid for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.

Authors:  Chaojun Zheng; Xiang Jin; Yu Zhu; Feizhou Lu; Jianyuan Jiang; Xinlei Xia
Journal:  Eur Spine J       Date:  2017-03-31       Impact factor: 3.134

2.  Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy.

Authors:  Akihiro Tsukahara; Takafumi Hosokawa; Daisuke Nishioka; Takuya Kotani; Shimon Ishida; Tohru Takeuchi; Fumiharu Kimura; Shigeki Arawaka
Journal:  Sci Rep       Date:  2021-11-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.